ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc (GLUE)

6.08
0.12
(2.01%)
Closed September 13 4:00PM
6.08
0.00
(0.00%)
After Hours: 7:25PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
6.08
Bid
5.50
Ask
6.30
Volume
208,278
5.64 Day's Range 6.26
2.44 52 Week Range 35.96
Market Cap
Previous Close
5.96
Open
6.07
Last Trade
7
@
6.2786
Last Trade Time
Financial Volume
$ 1,244,933
VWAP
5.9773
Average Volume (3m)
210,169
Shares Outstanding
61,372,824
Dividend Yield
-
PE Ratio
-2.76
Earnings Per Share (EPS)
-2.21
Revenue
-
Net Profit
-135.35M

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enable... Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Monte Rosa Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GLUE. The last closing price for Monte Rosa Therapeutics was $5.96. Over the last year, Monte Rosa Therapeutics shares have traded in a share price range of $ 2.44 to $ 35.96.

Monte Rosa Therapeutics currently has 61,372,824 shares outstanding. The market capitalization of Monte Rosa Therapeutics is $365.78 million. Monte Rosa Therapeutics has a price to earnings ratio (PE ratio) of -2.76.

GLUE Latest News

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines...

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases...

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial...

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines...

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose...

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.2124.84599589324.877.084.57022514196.13144578CS
42.4969.35933147633.597.083.322369084.82115261CS
12006.088.843.322101695.09163373CS
260.132.184873949585.958.842.442206384.8095087CS
52-29.57-82.945301542835.6535.962.442048738.91288613CS
156-15.92-72.36363636362245.562.4420995310.47530736CS
2600006.68000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NOVVUNova Vision Acquisition Corporation
$ 41.00
(207.35%)
17.4k
NOVVNova Vision Acquisition Corporation
$ 37.0001
(200.08%)
205.22k
SMXSMX Security Matters Public Company
$ 5.85
(138.78%)
50.1M
OMICSingular Genomics Systems Inc
$ 12.38
(119.12%)
2.87M
TILInstill Bio Inc
$ 84.75
(82.41%)
3.91M
GSIWGarden Stage Ltd
$ 2.9693
(-75.66%)
4.24M
UPCUniverse Pharmaceuticals Inc
$ 0.55
(-67.07%)
30.45M
VMARVision Marine Technologies Inc
$ 0.77
(-48.67%)
34.54M
PRLDPrelude Therapeutics Inc
$ 2.775
(-42.55%)
2.49M
CNEYCN Energy Group Inc
$ 0.4335
(-37.17%)
5.06M
NVDANVIDIA Corporation
$ 119.10
(-0.03%)
238.43M
XXII22nd Century Group Inc
$ 0.3447
(28.00%)
183.73M
IMRXImmuneering Corporation
$ 2.02
(41.26%)
136.36M
SQQQProShares UltraPro Short QQQ
$ 8.17
(-1.33%)
127.78M
MULNMullen Automotive Inc
$ 0.1328
(-20.48%)
120.81M

Your Recent History

Delayed Upgrade Clock